Sugi Predict

Sugi Predict / Compounds / SCHEMBL4671691

SCHEMBL4671691

SCHEMBL4671691

Cc1cc(B2OC(C)(C)C(C)(C)O2)cc(C)n1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 13/20 0.43
▸ LIPG Q9Y5X9 13/20 0.43
▸ IRAK4 Q9NWZ3 1/20 0.41
▸ FFAR1 O14842 1/20 0.37
▸ CA1 P00915 2/20 0.36
▸ CA2 P00918 2/20 0.36
▸ CA9 Q16790 2/20 0.36
▸ CA12 O43570 1/20 0.36
▸ CA3 P07451 1/20 0.36
▸ CA4 P22748 1/20 0.36
▸ CA6 P23280 1/20 0.36
▸ CA5A P35218 1/20 0.36
▸ CA7 P43166 1/20 0.36
▸ CA14 Q9ULX7 1/20 0.36
▸ CA5B Q9Y2D0 1/20 0.36
▸ SNCA P37840 1/20 0.35
▸ F11 P03951 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2186152 0.87 NOS3 (0.44) LPLLIPGIRAK4FFAR1CA1
SCHEMBL17667853 0.87 LPL (0.38) LPLLIPGIRAK4FFAR1CA1
SCHEMBL29573905 0.87 LPL (0.43) LPLLIPGIRAK4FFAR1CA1
SCHEMBL2326164 0.87 LPL (0.38) LPLLIPGIRAK4FFAR1CA1
SCHEMBL16534924 0.87 LPL (0.43) LPLLIPGIRAK4FFAR1CA1
SCHEMBL29384616 0.87 LPL (0.38) LPLLIPGIRAK4FFAR1CA1
SCHEMBL18861184 0.87 LPL (0.38) LPLLIPGIRAK4FFAR1CA1
SCHEMBL25395107 0.86 LPL (0.40) LPLLIPGIRAK4FFAR1CA1
SCHEMBL3670935 0.85 SNCA (0.39) LPLLIPGIRAK4FFAR1CA1
SCHEMBL29383901 0.85 SNCA (0.39) LPLLIPGIRAK4FFAR1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735114-A1 SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES Masarykova Univerzita (CZ) 2026-05-06 — — EP disclosed
US-12617796-B2 Antagonists of the adenosine A2a receptor JANSSEN PHARMACEUTICA NV (BE) 2026-05-05 — — US disclosed
WO-2026090477-A1 HELICASE INHIBITORS AND USES THEREOF KIMIA THERAPEUTICS, INC. (US) 2026-04-30 — — WO disclosed
US-20260098028-A1 Compounds and Their Use for Treatment of Hemoglobinopathies BRISTOL-MYERS SQUIBB COMPANY (US) 2026-04-09 — — US disclosed
US-12528815-B2 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer NXERA PHARMA UK LIMITED (GB) 2026-01-20 — — US disclosed
EP-4676927-A1 HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS Synnovation Therapeutics, Inc. (US) 2026-01-14 — — EP disclosed
EP-4674484-A2 THIENOPYRROLE COMPOUNDS Gilead Sciences, Inc. (US) 2026-01-07 — — EP disclosed
US-20250352550-A1 SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE UNIV MASARYKOVA (CZ) 2025-11-20 — — US disclosed
US-12441711-B2 Compounds and their use for treatment of hemoglobinopathies BRISTOL-MYERS SQUIBB COMPANY (US) 2025-10-14 — — US disclosed
US-20250313567-A1 IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS INCYTE CORPORATION 2025-10-09 — — US disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 — — US disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 — — US disclosed
EP-2366699-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2011-09-21 — — EP disclosed
WO-2011070131-A1 5-AMINO- 4-HYDROXYPENTOYL AMIDES TIBOTEC PHARMACEUTICALS (IE) 2011-06-16 — — WO disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 — — US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 — — US disclosed
WO-2010038465-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF 旭化成ファーマ株式会社 (JP) 2010-04-08 — — WO disclosed
CN-100491323-C Biaryloxymethylarenecarboxylic acids compound HOFFMANN LA ROCHE (CH) 2009-05-27 — — CN disclosed
EP-1663936-B1 BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS HOFFMANN LA ROCHE (CH) 2008-01-09 — — EP disclosed
CN-1812956-A Biaryloxymethylarenecarboxylic acids as glycogen synthase activator HOFFMANN LA ROCHE (CH) 2006-08-02 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12617796-B2 Antagonists of the adenosine A2a receptor ADORA2A, ADORA2B, ADORA3 LPL 3472/4885LIPG 3636/4885IRAK4 2309/4885
US-20250352550-A1 SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE FLT3, ROS1, MAP4K2 LPL 4726/4885LIPG 3782/4885IRAK4 66/4885
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 LPL 3942/4885LIPG 3515/4885IRAK4 14/4885
US-12528815-B2 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer ADORA1, ADORA3, OPRL1 LPL 3394/4885LIPG 4615/4885IRAK4 1940/4885
US-12441711-B2 Compounds and their use for treatment of hemoglobinopathies HBG1, HBG2, HBB LPL 823/4885LIPG 640/4885IRAK4 4775/4885
US-20260098028-A1 Compounds and Their Use for Treatment of Hemoglobinopathies HBZ, HBG2, HBB LPL 1712/4885LIPG 1552/4885IRAK4 4720/4885
US-20250313567-A1 IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS ADORA2A, ADORA2B, ADORA1 LPL 4054/4885LIPG 3519/4885IRAK4 1086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.